Cargando…

International workshop on assessment of upper limb function in Duchenne Muscular Dystrophy: Rome, 15–16 February 2012

Detalles Bibliográficos
Autores principales:	Mercuri, Eugenio, McDonald, Craig, Mayhew, Anna, Florence, Julaine, Mazzone, Elena, Bianco, Flaviana, Decostre, Valerie, Servais, Laurent, Ricotti, Valeria, Goemans, Nathalie, Vroom, Elizabeth
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Pergamon Press 2012
Materias:	Workshop Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3500683/ https://www.ncbi.nlm.nih.gov/pubmed/22795657 http://dx.doi.org/10.1016/j.nmd.2012.06.006

Ejemplares similares

The NorthStar Ambulatory Assessment in Duchenne muscular dystrophy: considerations for the design of clinical trials
por: Ricotti, Valeria, et al.
Publicado: (2016)

Determining minimal clinically important differences in the North Star Ambulatory Assessment (NSAA) for patients with Duchenne muscular dystrophy
por: Ayyar Gupta, Vandana, et al.
Publicado: (2023)

Suitability of external controls for drug evaluation in Duchenne muscular dystrophy
por: Goemans, Nathalie, et al.
Publicado: (2020)

Letter to the Editor: In response to P.R. Clemens et al., Efficacy and Safety of Viltolarsen in Boys with Duchenne Muscular Dystrophy: Results From the Phase 2, Open-Label, 4-Year Extension Study, and Long-Term Functional Efficacy and Safety of Viltolarsen in Patients with Duchenne Muscular Dystrophy
por: Muntoni, Francesco, et al.
Publicado: (2023)

Gene therapy in Duchenne muscular dystrophy: Identifying and preparing for the challenges ahead
por: Heslop, Emma, et al.
Publicado: (2021)

Wearable full-body motion tracking of activities of daily living predicts disease trajectory in Duchenne muscular dystrophy
por: Ricotti, Valeria, et al.
Publicado: (2023)

Revised North Star Ambulatory Assessment for Young Boys with Duchenne Muscular Dystrophy
por: Mercuri, Eugenio, et al.
Publicado: (2016)

Increased dystrophin production with golodirsen in patients with Duchenne muscular dystrophy
por: Frank, Diane E., et al.
Publicado: (2020)

Imperatives for DUCHENNE MD: a Simplified Guide to Comprehensive Care for Duchenne Muscular Dystrophy
por: Kinnett, Kathi, et al.
Publicado: (2015)

24 Month Longitudinal Data in Ambulant Boys with Duchenne Muscular Dystrophy
por: Mazzone, Elena Stacy, et al.
Publicado: (2013)

Early Gross Motor Milestones in Duchenne Muscular Dystrophy
por: Norcia, Giulia, et al.
Publicado: (2021)

Detecting early signs in Duchenne muscular dystrophy: comprehensive review and diagnostic implications
por: Mercuri, Eugenio, et al.
Publicado: (2023)

Upper limb disease evolution in exon 53 skipping eligible patients with Duchenne muscular dystrophy
por: Lilien, Charlotte, et al.
Publicado: (2021)

Language Development in Preschool Duchenne Muscular Dystrophy Boys
por: Chieffo, Daniela Pia Rosaria, et al.
Publicado: (2022)

Comparison of Long-term Ambulatory Function in Patients with Duchenne Muscular Dystrophy Treated with Eteplirsen and Matched Natural History Controls
por: Mendell, Jerry R., et al.
Publicado: (2021)

Development of Exon Skipping Therapies for Duchenne Muscular Dystrophy: A Critical Review and a Perspective on the Outstanding Issues
por: Aartsma-Rus, Annemieke, et al.
Publicado: (2017)

Correction: 24 Month Longitudinal Data in Ambulant Boys with Duchenne Muscular Dystrophy
por: Mazzone, Elena Stacy, et al.
Publicado: (2013)

A Comparison of Caregiver and Patient Preferences for Treating Duchenne Muscular Dystrophy
por: Crossnohere, Norah L., et al.
Publicado: (2022)

Long-term natural history data in Duchenne muscular dystrophy ambulant patients with mutations amenable to skip exons 44, 45, 51 and 53
por: Brogna, Claudia, et al.
Publicado: (2019)

DMD Genotypes and Motor Function in Duchenne Muscular Dystrophy: A Multi-institution Meta-analysis With Implications for Clinical Trials
por: Muntoni, Francesco, et al.
Publicado: (2023)

The administration of antisense oligonucleotide golodirsen reduces pathological regeneration in patients with Duchenne muscular dystrophy
por: Scaglioni, Dominic, et al.
Publicado: (2021)

Lessons Learned from Discontinued Clinical Developments in Duchenne Muscular Dystrophy
por: Markati, Theodora, et al.
Publicado: (2021)

Correction: Long-term natural history data in Duchenne muscular dystrophy ambulant patients with mutations amenable to skip exons 44, 45, 51 and 53
por: Brogna, Claudia, et al.
Publicado: (2019)

Individualized Prediction of Changes in 6-Minute Walk Distance for Patients with Duchenne Muscular Dystrophy
por: Goemans, Nathalie, et al.
Publicado: (2016)

Longitudinal effect of eteplirsen versus historical control on ambulation in Duchenne muscular dystrophy
por: Mendell, Jerry R., et al.
Publicado: (2016)

Open-Label Evaluation of Eteplirsen in Patients with Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping: PROMOVI Trial
por: McDonald, Craig M., et al.
Publicado: (2021)

Survival in Duchenne muscular dystrophy
por: RALL, SUSANNE, et al.
Publicado: (2012)

Theragnosis for Duchenne Muscular Dystrophy
por: Luce, Leonela, et al.
Publicado: (2021)

Upper limb function in Duchenne muscular dystrophy: 24 month longitudinal data
por: Pane, Marika, et al.
Publicado: (2018)

Preimplantation genetic diagnosis associated to Duchenne muscular dystrophy
por: Bianco, Bianca, et al.
Publicado: (2017)

Longitudinal Alterations in Gait Features in Growing Children With Duchenne Muscular Dystrophy
por: Vandekerckhove, Ines, et al.
Publicado: (2022)

Electrical impedance myography for reducing sample size in Duchenne muscular dystrophy trials
por: Leitner, Melanie L., et al.
Publicado: (2019)

The 6 Minute Walk Test and Performance of Upper Limb in Ambulant Duchenne Muscular Dystrophy Boys
por: Pane, Marika, et al.
Publicado: (2014)

Cholesterol metabolism is a potential therapeutic target in Duchenne muscular dystrophy
por: Amor, Fatima, et al.
Publicado: (2021)

Efficacy and safety of deflazacort vs prednisone and placebo for Duchenne muscular dystrophy
por: Griggs, Robert C., et al.
Publicado: (2016)

Genetic modifiers of respiratory function in Duchenne muscular dystrophy
por: Bello, Luca, et al.
Publicado: (2020)

Muscle-MRI and Functional Levels for the Evaluation of Upper Limbs in Duchenne Muscular Dystrophy: A Critical Review of the Literature
por: Cristiano, Lara, et al.
Publicado: (2022)

Hypokalemia complicating Duchenne muscular dystrophy.
por: McDonald, B., et al.
Publicado: (1987)

The role of fibrosis in Duchenne muscular dystrophy
por: KLINGLER, WERNER, et al.
Publicado: (2012)

Delay in Diagnosis of Duchenne Muscular Dystrophy
por: Rao, Vamshi K., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_gu501v9qahgmio2thr2u7ud1h8